Extended Thyroid Panel
The thyroid gland is an endocrine gland that produces hormones that have many functions. Regulation of metabolism is one of the main functions of the hormones produced in the thyroid gland. Two of the hormones produces in the thyroid gland are Thyroxine (T4) and Triiodothyronine (T3). Both hormones require iodine for production, which is brought into the body by the food a person eats. Dairy products, fish, and iodized salt are common sources of dietary iodine. Since T4 and T3 production occur to meet the needs of the body, the level of these hormones is monitored by the hypothalamus (a control gland in the brain). It produces thyroid-releasing hormone that stimulates the pituitary gland to produce thyroid-stimulating hormone that stimulates thyroid hormone production. Dysfunction of the thyroid gland affects about 2-3% of the population. Typically thyroid issues are seen more commonly in women, usually in their late 40s or early 50s. Since the hormone production and stimulation loop is complex, determining the etiology of thyroid gland dysfunction can be difficult. A thyroid panel is a complement of tests that can aid a physician in diagnosing thyroid dysfunction. Thyroid panel is used to evaluate thyroid function and help diagnose thyroid diseases related to hypo and hyperthyroidism. The preferred test to screen for thyroid diseases is TSH. If THS is abnormal total T4 and free T4 should be ordered. In addition, to rule out other diseases such as Rule out thyrotoxicosis Total T3 and or Free T3 will be also ordered. Antibody to thyroglobulin and TPO are can be ordered when hypothyroidism especially autoimmune thyroidism is expected. The thyroid panel may include the following tests:
Thyroid-stimulating hormone (TSH): Produced by the anterior pituitary gland, TSH stimulates the thyroid gland to produce thyroid hormones. Secretion is stimulated by thyroid-releasing hormone from the hypothalamus. Free thyroid hormones (FT4 and FT3) work in a negative feedback loop to regulate the amount of TSH that is released from the pituitary gland. Dysregulation of TSH may either be a primary or secondary condition causing either hypo- or hyperthyroidism. An elevated TSH result usually means an underactive thyroid (hypothyroidism), whereas a decreased result means an overactive thyroid gland (hyperthyroidism) or excessive amounts of thyroid medication in an individual being treated for hypothyroidism.
Free T4: The thyroid gland converts iodine and the amino acid tyrosine into the thyroid hormones thyroxine (T4) and triiodothyronine (T3). These hormones function mainly to regulate metabolism and to regulate growth and development. Free T4 is the active form of thyroxine, and is generally thought to be a more accurate test for thyroid hormone function because it is not affected by protein levels. Free T4 represents just a fraction of total thyroxine ranging from 0.03% to 0.05%. A free T4 is commonly ordered in response to an abnormal thyroid-stimulating hormone (TSH) result. A high free T4 is consistent with hyperthyroidism, while a low result is consistent with hypothyroidism. The free thyroxine and sensitive TSH assays have similar sensitivities for detecting clinical hyperthyroidism and hypothyroidism. The free thyroxine test detects central hypothyroidism and monitors rapidly changing function better than the assay for TSH.
T4: Thyroxine (T4) is one of the major hormones produced by the thyroid gland.Thyroxine (T4) is the most abundant thyroid hormone and regulates metabolism. Almost all of the circulating thyroxine is bound to protein, either thyroid binding globulin (TBG), thyroid binding prealbumin (TBPA), or albumin, with <0.1% of total being active or free T4. The total thyroxine (T4) is used as a measure of thyroid function. This assay gives the value of total T4, protein-bound and unbound; therefore total T4 is a measure of total thyroid gland secretion of T4, both bound and free. Total T4 is influenced by serum thyroid hormone-binding activity.
T3: Triiodothyronine (T3) is also one of the thyroid hormones produced mainly from peripheral (liver and some other organs) conversion of thyroxine (T4), a prohormone. The T3 test is typically ordered to determine the functionality of the thyroid. T3 has greater biological activity than T4 and is considered the metabolic active form of thyroid hormone. T3’s activity is directly regulated by the thyroid binding globulin (TBG), because it binds less tightly than T4. Reduced total T3 levels occur in drug therapy with androgens, prednisone, dexamethasone, and glucocorticoids. T3 levels are also reduced in iodine deficiency, non-thyroidal disease also known as low T3 syndrome, anorexia nervosa, and following surgery to remove the thyroid gland. Increased T3 often occurs in hyperthyroidism known as T3 toxicosis. In T3 toxicosis T3 values are high while total or free thyroxine (T4 and FT4) are normal and TSH is low.
FT4I, Thyroxine Index: The free thyroxine index (FT4I) is a calculated value used to estimate the effects of protein or interfering drugs. It is an indirect measure of free hormone concentration and is based on the equilibrium relationship of FT4 and bound T4. FT4I is calculated as ((measured total T4) X (T3 resin uptake)). It provides an estimate of the level of free T4, because the T3 (or T4) resin uptake (i.e., thyroid hormone binding ratio) is an indirect estimate of the thyroid binding globulin (TBG) concentration (TBG binds 70% of circulating thyroid hormone). The unbound form of circulating T4, normally 0.03% of total serum T4, determines the amount of T4 available to cells.
Thyroid Stimulating Hormone Receptor Antibody: The thyroid-stimulating hormone receptor (TSH-R) is the primary antigen in autoimmune thyroid disease. This test detects heterogeneous IgG antibodies directed against the TSH receptor on thyroid cells. The test measures antibody indirectly by the stimulation of adenylyl cyclase to produce cAMP. Although TSH-R antibody is a marker of Graves disease, the test is not necessary for the diagnosis in most cases. TSH-R antibody is very rarely indicated, but may be helpful in pregnant women with a history of Graves disease. This is because TSH-R antibody may have some predictive value for neonatal thyrotoxicosis. TSH-R antibody may also be indicated for patients with symptoms consistent with Graves disease to confirm the diagnosis. High titers of TSH-R antibody are associated with relapse of hyperthyroidism at the end of a course of antithyroid drugs.
Thyroglobulin: Thyroglobulin is a large iodoglycoprotein produced by thyroid follicular cells of the thyroid gland. This protein serves as a precursor for synthesis of T3 and T4. Thyroglobulin is usually produced under the influence of thyroid stimulating hormone. Since this protein is produced only by the thyroid gland, testing for thyroglobulin is widely used for evaluation of thyroid status and function. Increase in thyroglobulin levels often indicates increased thyroid cellularity and/or enlargement of thyroid gland as may be the case in certain thyroid tumors. However, increase in thyroglobulin could be due to increased synthesis alone, where thyroid tissue (size and or cellularity) is normal, but thyroglobulin levels are higher. This is rare and mainly seen in infants with hypoplastic thyroid glands, ectopic thyroid tissue, dyshormonogenic goiter, congenital thyroid binding globulin (TGB) deficiency, or transient hyperthyroidism. Increased production of thyroglobulin due to increased cellularity is often seen with certain thyroid cancers. Therefore, thyroglobulin is used as a thyroid tumor marker for some thyroid cancers (e.g., differentiated epithelial carcinomas). In addition, this test may be used for the diagnosis of congenital hypothyroidism in newborns, where thyroglobulin levels are very low and sometimes undetectable. Measurement of thyroglobulin may also be used as an aid in the diagnosis of subacute thyroiditis, from thyrotoxicosis caused by covert administration of thyroid hormones, which is characterized by lower thyroglobulin levels due to thyroid hormone suppression of thyrotropin. The main use of this test is to monitor patients with differentiated thyroid cancers who are apparently disease-free after surgery and radioiodine therapy. In addition, tests for antibody to thyroglobulin should be ordered to rule out the presence of antibody to thyroglobulin, which might give falsely low results.
TSH:
- Screening for Thyroid Dysfunction
- Diagnosis of Hyperthyroidism (Decreased TSH)
- Diagnosis of Hypothyroidism (Elevated TSH)
- Monitoring thyroid hormone replacement therapy
- Monitoring anti-thyroid therapy (in hyperthyroidism)
Free T4:
- Diagnosis of hyperthyroidism
- Diagnosis of hypothyroidism
- Thyroid therapy monitoring
T4:
- Diagnosis of hyperthyroidism
- Diagnosis of hypothyroidism
- Therapy treatment monitoring
T3:
- In diagnosis of T3 hyperthyroidism
- As an aid in diagnosis of thyrotoxicosis such as in Graves Disease
- As an aid in confirmation of the diagnosis of conventional hyperthyroidism in which both serum T3 and T4 are increased
Free T4 Index:
- As an aid in diagnosis of hyperthyroidism
- As an aid in diagnosis of hypothyroidism
- Monitoring thyroid therapy
Thyroid Stimulating Hormone Receptor Antibody:
- Aids in diagnosing autoimmune hyperthyroidism such as Graves disease
- Differential diagnosis of Graves disease and toxic goiter
- Aids diagnosis of neonatal thyrotoxicosis
- Therapy monitoring
Thyroglobulin:
- Used as a tumor marker for diagnosis of certain thyroid cancers (thyroid carcinoma, follicular carcinoma, Hürthle cell carcinoma)
- Differential diagnosis of Graves disease
- Differential diagnosis of hyperthyroidism
- As an aid in diagnosis of subacute thyroiditis
- Treatment monitoring
TSH
Increased in:
- Hypothyroidism
- Mild increase in subclinical hypothyroidism, which is defined as a mild increase in serum TSH and normal free thyroxine and triiodothyronine levels
Decreased in:
- Hyperthyroidism
- Graves disease
- Thyroiditis
- Toxic multinodular goiter
- Toxic adenomas
- Acute medical or surgical illness
- Pituitary hypothyroidism
- In some drugs such dopamine
- High-dose corticosteroids
- Mild decrease in subclinical hyperthyroidism, which is defined as a mild decrease in serum TSH and normal free thyroxine and triiodothyronine levels
Free T4
Increased in:
- Hyperthyroidism
- Some nonthyroid illnesses such as psychiatric disease
- Patients taking amiodarone and -blockers
Decreased in:
- Hypothyroidism
- Some nonthyroid illnesses
- Patients taking phenytoin
T4
Increased in:
- Hyperthyroidism, when thyroid-binding globulin (TBG) is increased (e.g., pregnancy, drug)
- Genetic increase of thyroxine binding proteins
- Acute hepatitis
- Pregnancy
- Some drugs such as amiodarone, high-dose -blockers
Decreased in:
- Hypothyroidism, low TBG due to illness or drugs
- Congenital absence of TBG
- Some drugs such as phenytoin, carbamazepine, and androgens
T3
Increased in:
- Hyperthyroidism
- Thyrotoxicosis
- With elevated levels of thyroid-binding globulin
Decreased in:
- Hypothyroidism
- Nonthyroidal illness
- Decreased thyroid-binding globulin
- Decreased in use of some drugs: amiodarone, corticosteroids, androgens, dexamethasone
Free T4 Index
Increased in:
- Hyperthyroidism
- Some drugs such as amiodarone, ß-blockers
Decreased in:
- Hypothyroidism
- Some nonthyroid illness
Thyroid Stimulating Hormone Receptor Antibody
Increased in:
- Autoimmune hyperthyroidism (Graves disease)
- Transient neonatal thyrotoxicosis
Thyroglobulin
Increased in:
- Hyperthyroidism
- Subacute thyroiditis
- Untreated thyroid carcinomas of certain types (papillary, follicular, and Hürthle)
Decreased in:
- Hyperthyroidism (of any kind of etiology)
- Patients with thyroglobulin autoantibodies
- Patients with total or partial thyroidectomy
- Some other forms of thyroiditis
| Analyte | Reference Range |
| TSH | 0.4 – 6 mcU/mL |
| Free T4 | 0.8 – 2.0 ng/dL |
| T4 | 5.5 – 12.5 g/dL |
| T3 | 95–190 ng/dL (1.5–2.9 nmol/L) |
| Free T4 Index | 6.5 – 12.5 |
| Thyroid Stimulating Hormone Receptor Antibody | <1.75 IU/L |
| Thyroglobulin | 3–42 ng/mL (mcg/L) |
TSH: Immunoassay, Free T4: Immunoassay, Equilibrium dialysis/HPLC/Mass spec, T4: Radioimmunoassay (RIA), Enzyme-linked immunosorbent assay (ELISA), Enzyme multiplied immunoassay (EMIT), T3: Radioactive immunoassay, Enzyme immunoassay (EIA), Electrochemiluminescence immunoassay (ECLIA), ELISA, Free T4 Index: Immunoassay, ELISA, Thyroid Stimulating Hormone Receptor Antibody: Immunoassay, ELISA, Thyroglobulin: Immunoassay, ELISA.
TSH: Serum or plasma
Free T4: Serum or plasma
T4: Serum or plasma
T3: Serum or Plasma
Free T4 Index: Serum or Plasma
Thyroid Stimulating Hormone Receptor Antibody: Serum or plasma
Thyroglobulin: Serum or plasma
Stability
- Ambient: 2-5 days
- Refrigeration: 7-14 days
| Test | Turnaround Time |
| TSH | 1-3 days |
| Free T4 | 1-3 days |
| T4 | 1-3 days |
| T3 | 1-3 days |
| Free T4 Index | 1-3 days |
| Thyroid Stimulating Hormone Receptor Antibody | 1-3 days |
| Thyroglobulin | 1-3 days |
- Am Fam Physician. 2005;72:623. [PMID: 16127951]
- Lancet. 2003 Aug 9;362(9382):459-68. [PMID: 12927435]
- Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):341-9. [PMID: 19961039]
- ExpClinEndocrinol Diabetes. 1998;106Suppl 4:S29-33. [PMID: 9867193]
- Horm Res. 1996;45(3-5):142-7. [PMID: 8964573]
- Am Fam Physician. 2005;72:1517. [PMID: 16273818]
- Clin Chem. 2005;51:1480. [PMID: 15961550]
- Eur J Endocrinol. 2006;154:633. [PMID: 16645008]
- Arch Intern Med. 1998;158:266. [PMID: 9472207]
- Lancet. 2001;357:619. [PMID: 11558500]
- Clin Chem. 2005;51:1480. [PMID: 15961550]
- Clin Lab Med. 1993 Sep;13(3):653-72. [PMID: 8222580]
- Am Fam Physician. 1995 Dec;52(8):2325-30. [PMID: 7484724]
- Drugs Aging. 2005;22:23. [PMID: 15663347]
- Pediatrics. 2006;117:2290. [PMID: 16740880]
- EndocrinolMetabClin North Am. 2007 Sep;36(3):579-94, v. [PMID: 17673120]
- Clin Lab Med. 1993 Sep;13(3):599-630. [PMID: 8222577]
- Lancet. 2001;357:619. [PMID: 11558500]
- EndocrinolMetabClin North Am. 2000;29:339. [PMID: 10874533]
- HormMetab Res. 2005;37:745. [PMID: 16372228]
- HormMetab Res. 2005;37:741. [PMID: 16372227]
- J Clin Invest. 2005;115:1972. [PMID: 16075037]
- Treat Endocrinol. 2005;4:31. [PMID: 15649099]
- Minerva Endocrinol 2004;29:161. [PMID: 15765026]
- Curr Treat Options Oncol 2005;6:323. [PMID: 15967085]
- Med SciMonit 2005;11:RA368. [PMID: 16319807]
- SeminNucl Med 2005;35:257. [PMID: 16150246]
- Bishop ML, Duben-Engelkirk JL, Fody EP.Clinical Chemistry Principles, Procedures,
- Correlations. Philadelphia. Lippincott (1996).
- Starrenburg-Razenberg AJ, Castro Cabezas M, Gan IM, Njo TL, Rietveld AP, Elte JW.
- Four patients with hypothyroid Graves' disease.Neth J Med. 2010 Apr;68(4):178-80.